William Z. Potter
#113,824
Most Influential Person Now
William Z. Potter's AcademicInfluence.com Rankings
William Z. Pottermedical Degrees
Medical
#1593
World Rank
#1949
Historical Rank
Toxicology
#16
World Rank
#18
Historical Rank
Pharmacology
#142
World Rank
#178
Historical Rank

William Z. Potterphilosophy Degrees
Philosophy
#4867
World Rank
#7533
Historical Rank
Logic
#2240
World Rank
#3188
Historical Rank

Download Badge
Medical Philosophy
William Z. Potter's Degrees
- PhD Pharmacology University of California, San Francisco
- Doctorate Medicine University of California, San Francisco
Why Is William Z. Potter Influential?
(Suggest an Edit or Addition)William Z. Potter's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. (1973) (1667)
- Acetaminophen-Induced Hepatic Necrosis (1974) (1479)
- Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. (1973) (1443)
- Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. (1973) (1152)
- Bupropion: a review of its mechanism of antidepressant activity. (1995) (733)
- Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. (1997) (562)
- Acetaminophen‐induced hepatic injury: Protective role of glutathione in man and rationale for therapy (1974) (485)
- Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. (1973) (480)
- Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. (2004) (454)
- Cerebrospinal fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. (1990) (401)
- Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. (2008) (398)
- Signal transduction pathways. Molecular targets for lithium's actions. (1995) (339)
- Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. (2002) (335)
- Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites (1975) (293)
- Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. (1974) (288)
- Diagnosing diagnoses. Receiver operating characteristic methods and psychiatry. (1989) (281)
- Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. (1974) (280)
- Assessing and interpreting treatment effects in longitudinal clinical trials with missing data (2003) (232)
- The responsiveness of the Hamilton Depression Rating Scale. (2000) (229)
- Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. (1986) (210)
- LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress (2003) (206)
- Plasma norepinephrine level in affective disorders. Relationship to melancholia. (1985) (185)
- A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder (2012) (177)
- Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. (1989) (173)
- Report of the task force on designing clinical trials in early (predementia) AD (2010) (162)
- Chronic Sodium Valproate Selectively Decreases Protein Kinase C α and ε In Vitro (1994) (160)
- The pharmacologic treatment of depression. (1991) (156)
- Translating Glutamate: From Pathophysiology to Treatment (2011) (153)
- Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. (1974) (149)
- Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients. (1982) (137)
- Dual Monoamine Modulation for Improved Treatment of Major Depressive Disorder (2003) (136)
- Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. (1992) (132)
- Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites. (1985) (124)
- Cerebrospinal Fluid Homovanillic Acid Predicts Behavioral Response to Stimulants in 45 Boys with Attention Deficit/Hyperactivity Disorder (1996) (124)
- Bupropion in depression. II. The role of metabolites in clinical outcome. (1988) (114)
- Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia (1996) (110)
- Metabolism of Tricyclic Antidepressants (1999) (109)
- Comparative Tolerability Profiles of the Newer versus Older Antidepressants (1994) (103)
- Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF (2015) (102)
- Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study (2003) (99)
- Modulation of Protein Kinase C Isozymes and Substrates by Lithium: The Role of Myo-inositol (1996) (99)
- Exaggerated orthostatic responsivity of plasma norepinephrine in depression. (1985) (99)
- Hepatic necrosis caused by furosemide (1974) (98)
- A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia (2020) (96)
- Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response (1986) (96)
- Clinical Assessment of Norepinephrine Transporter Blockade Through Biochemical and Pharmacological Profiles (2004) (95)
- Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. (1990) (94)
- The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects. (1991) (93)
- Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment. (1995) (91)
- Active metabolites of imipramine and desipramine in man (1982) (90)
- Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. (1989) (89)
- Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. (1979) (89)
- Stimulant drug treatment of hyperactivity: Biochemical correlates (1990) (87)
- Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. (1988) (87)
- Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders. A replication and new findings. (1984) (86)
- A neuroanatomical and biochemical basis for attention deficit disorder with hyperactivity in children: a defect in tonic adrenaline mediated inhibition of locus coeruleus stimulation. (1989) (85)
- Circadian covariation of norepinephrine and serotonin in the locus coeruleus and dorsal raphe nucleus in the rat (1986) (83)
- Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. (1994) (82)
- Desipramine pharmacokinetics in Chinese and Caucasian volunteers. (1984) (82)
- Increase in AP-1 Transcription Factor DNA Binding Activity by Valproic Acid (1997) (81)
- Attenuation of Cyclic AMP Production by Carbamazepine (1996) (80)
- The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. (2008) (80)
- Bupropion in depression. I. Biochemical effects and clinical response. (1988) (79)
- In Vivo Evidence that Lithium Inactivates Gi Modulation of Adenylate Cyclase in Brain (1992) (78)
- Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. (1994) (78)
- Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism. (1978) (78)
- Metabolic activation of furosemide to a chemically reactive, hepatotoxic metabolite. (1976) (77)
- Catecholamines in depression: an update. (1994) (76)
- The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. (1991) (75)
- The problem of measurement error in multisite clinical trials. (1998) (75)
- Clozapine in China: a review and preview of US/PRC collaboration (2004) (74)
- Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial (2018) (74)
- Psychoses associated with bupropion treatment. (1985) (73)
- Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain. (1990) (72)
- Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. (1996) (72)
- Single-dose kinetics predict steady-state concentrations on imipramine and desipramine. (1980) (70)
- The Effects of ECT on Brain Glucose: A Pilot FDG PET Study (1999) (69)
- NIMH workshop report on treatment of bipolar disorder. (1990) (67)
- The effects of intravenous clomipramine on neurohormones in normal subjects. (1989) (67)
- Use of ECT with treatment-resistant depressed patients at the National Institute of Mental Health. (1981) (67)
- Clorgyline. A new treatment for patients with refractory rapid-cycling disorder. (1982) (66)
- The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials (2001) (65)
- Effect of low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. (1982) (61)
- Idazoxan: a selective alpha 2-antagonist and effective sustained antidepressant in two bipolar depressed patients. (1989) (61)
- Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs (2014) (61)
- Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH (1999) (61)
- The Impact of Restrictive Entry Criterion During the Placebo Lead‐in Period (2000) (60)
- Effects of desmethylimipramine on plasma norepinephrine, pulse, and blood pressure (1983) (58)
- High Levels of Gsα in Platelets of Euthymic Patients With Bipolar Affective Disorder (1997) (56)
- Monoamine neurotransmitter interactions and the prediction of antidepressant response. (1987) (53)
- A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. (1999) (52)
- Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. (1993) (52)
- Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography (2002) (52)
- Abnormal neuroendocrine responsivity to acute I.V. clomipramine challenge in depressed patients (1990) (51)
- The Role of Metabolites of Antidepressants in the Treatment of Depression (1997) (50)
- Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. (1985) (48)
- Lithium administration modulates platelet Gi in humans. (1992) (47)
- Idazoxan, an ??2 Antagonist, Augments Fluphenazine in: Schizophrenic Patients (1993) (47)
- Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women. (1991) (46)
- Concentration gradient of CSF monoamine metabolites in children and adolescents (1988) (46)
- Electroconvulsive therapy--a modern medical procedure. (1993) (46)
- Biochemical changes after hepatic injury from toxic doses of acetaminophen or furosemide. (1976) (46)
- Specific norepinephrine and serotonin uptake inhibitors in man: A crossover study with pharmacokinetic, biochemical, neuroendocrine and behavioral parameters (1981) (46)
- Toxic Drug Reactions (1975) (45)
- Fluctuating high urinary phenylethylamine excretion rates in some bipolar affective disorder patients (1982) (45)
- Effects of Valproic Acid on β-adrenergic Receptors, G-proteins, and Adenylyl Cyclase in Rat C6 Glioma Cells (1996) (45)
- The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5‐hydroxyindoleacetic acid ratio (1987) (44)
- Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study (1991) (44)
- Effects of electroconvulsive treatment on somatostattn, neuropeptide Y, endothelin, and neurokinin a concentrations in cerebrospinal fluid of depressed patients: A pilot study (1995) (43)
- NOREPINEPHRINE METABOLITE STUDIES IN AFFECTIVE ILLNESS (1979) (43)
- Discovering translational biomarkers in neurodevelopmental disorders (2018) (42)
- Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. (1996) (42)
- Effects of antidepressant treatments on dopamine turnover in depressed patients. (1983) (42)
- Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain. (2012) (41)
- Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures. (1985) (41)
- High correlation of norepinephrine and its major metabolite excretion rates. (1982) (40)
- Altered hydroxydesipramine concentrations in elderly depressed patients (1982) (39)
- Biochemical changes after hepatic injury by allyl alcohol and N-hydroxy-2-acetylaminofluorene. (1976) (39)
- Electroconvulsive treatment and lithium carbonate. Their effects on norepinephrine metabolism in patients with primary, major depressions. (1983) (38)
- Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS) (2020) (38)
- Plasma norepinephrine in chronic schizophrenia. (1990) (38)
- High reverse T3 levels in manic and unipolar depressed women (1982) (38)
- The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development (2018) (37)
- Clinical studies on norepinephrine metabolism: How to interpret the numbers (1986) (37)
- 8 – Sources of Variance in Clinical Studies of MHPG (1983) (37)
- Second-generation antidepressants. (1984) (36)
- Rating the Raters: Assessing the Quality of Hamilton Rating Scale for Depression Clinical Interviews in Two Industry-sponsored Clinical Drug Trials (2006) (36)
- Neurophysiologic Correlates of Side Effects in Normal Subjects Randomized to Venlafaxine or Placebo (2005) (34)
- Signal transduction modulation by lithium: cell culture, cerebral microdialysis and human studies. (1991) (34)
- Chronic Li+ attenuates agonist- and phorbol ester-mediated Na+/H+ antiporter activity in HL-60 cells. (1990) (34)
- Conceptual, Regulatory and Strategic Imperatives in the Early Days of EEG-Based Biomarker Validation for Neurodevelopmental Disabilities (2019) (33)
- Bipolar depression: specific treatments. (1998) (32)
- Gender Differences in Brain Metabolic and Plasma Catecholamine Responses to Alpha2-Adrenoceptor Blockade (1997) (30)
- Plasma steady‐state concentrations of hydroxylated metabolites of clomipramine (1982) (30)
- Concentrations of desipramine in elderly women. (1981) (30)
- Plasma haloperidol levels and clinical response in acute schizophrenia. (1982) (30)
- B : ALGORITHMS FOR THE TREATMENT OF BIPOLAR, MANIC-DEPRESSIVE ILLNESS (1995) (30)
- Reduction of norepinephrine turnover by serotonergic drug in man. (1984) (30)
- Hypothalamic-pituitary-adrenal axis and monoamine transmitter activity in depression: A pilot study of central and peripheral effects of electroconvulsive therapy (1991) (29)
- Cerebral glucose metabolism during pharmacologic studies: test-retest under placebo conditions. (1996) (29)
- Characterization of β 1- and β 2-adrenoceptor subtypes in the rat sinoatrial node and stellate ganglia by quantitative autoradiography (1989) (28)
- Changes in Brain Function during Administration of Venlafaxine or Placebo to Normal Subjects (2008) (28)
- Active metabolites of antidepressants: pharmacodynamics and relevant pharmacokinetics. (1984) (28)
- Effects of renal clearance on plasma concentrations of homovanillic acid. Methodologic cautions. (1989) (27)
- Possible mechanism of isoniazid related hepatic injury (1974) (27)
- Treatment of bipolar depressive mood disorders: Algorithms for pharmacotherapy. (1997) (27)
- Reliability of urinary monoamine and metabolite output measurements in depressed patients. (1983) (27)
- Dopamine D1 receptor in rat brain: a quantitative autoradiographic study with125I-SCH 23982 (1987) (27)
- Characterization of beta 1- and beta 2-adrenoceptor subtypes in the rat atrioventricular node by quantitative autoradiography. (1988) (27)
- Is bigger better for depression trials? (2008) (26)
- Hormonal responses to zimelidine and desipramine in depressed patients (1984) (25)
- Behavioral and endocrine responses to clomipramine in panic disorder patients with or without alcoholism (1995) (25)
- Axonal transport of dopamine D1 receptors in the rat brain (1987) (25)
- Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. (1991) (24)
- Five antidepressant treatments in depressed patients. Effects on urinary serotonin and 5-hydroxyindoleacetic acid output. (1984) (24)
- Tricyclic antidepressants do not alter thyroid hormone levels in patients suffering from a major affective disorder (1981) (24)
- A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms (2019) (23)
- High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder. (1997) (23)
- The effect of desmethylimipramine on the metabolism of norepinephrine. (1984) (23)
- Biomarkers in psychotropic drug development: integration of data across multiple domains. (2005) (23)
- Effects of amitriptyline, desipramine and zimeldine, alone and in combination with ethanol, on information processing and memory in healthy volunteers (1983) (23)
- Drug metabolism in the production of liver injury. (1975) (22)
- Imaging as a biomarker in drug discovery for Alzheimer’s disease: is MRI a suitable technology? (2014) (22)
- Noradrenergic Function in Depressive Disorders (1993) (21)
- Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers (2020) (21)
- Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. (1993) (21)
- Down-regulation of PKC alpha by lithium in vitro. (1995) (20)
- Antidepressants, Metabolites, and Apparent Drug Resistance (1990) (20)
- Rapid mood cycles after a noradrenergic but not a serotonergic antidepressant. (1979) (20)
- High correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates. (1988) (19)
- Intravenous alprazolam challenge in normal subjects (1989) (19)
- Chronic electroconvulsive shock increases D-1 receptor binding in rat substantia nigra. (1989) (19)
- Algorithms for the treatment of bipolar manic-depressive illness. (1995) (18)
- Alterations in Cyclic AMP Generation and G Protein Subunits following Transient Ischemia in Gerbil Hippocampus (1995) (17)
- Methodological issues in the measurement of urinary MHPG (1981) (17)
- Lack of seasonal variation in pediatric lumbar cerebrospinal fluid neurotransmitter metabolite concentrations (1989) (17)
- Dissociation of norepinephrine turnover from alpha‐2 responses after clorgiline (1988) (16)
- Familial hypokalemia associated with renal interstitial fibrosis. (1974) (16)
- High positive correlation between urinary free tyramine excretion rate and "whole body" norepinephrine turnover in depressed patients. (1982) (16)
- PROOF OF CONCEPT: FUNCTIONAL MODELS FOR DRUG DEVELOPMENT IN HUMANS (2002) (16)
- Effects of S-adenosyl-methionine on plasma norepinephrine, blood pressure, and heart rate in healthy volunteers (1986) (15)
- Neurochemical and neuroendocrine dysregulation in affective disorders. (1986) (15)
- Common mechanism of action of biochemically “specific” antidepressants (1984) (15)
- Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model. (2007) (15)
- The Tyramine Pressor Test May Have Limited Sensitivity, Especially in the Presence of Dual Serotonin/Norepinephrine Uptake Inhibition★ (2002) (15)
- Differences in lithium effects in depressed and healthy subjects (1985) (15)
- Lymphocyte beta adrenergic receptor function versus catecholamines in depression (1988) (14)
- The Biology of Affective Illness: Amine Neurotransmitters and Drug Response (1978) (14)
- Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model. (2016) (14)
- Possible Role of Hydrazine Group in Hypoglycemia Associated with the Use of Certain Monoamine-oxidase Inhibitors (MAOI's) (1969) (14)
- Responses to α 2-adrenoceptor blockade by idazoxan in healthy male and female volunteers (1997) (14)
- Down-regulation of beta receptors by desipramine in vitro involves PKC/phospholipase A2. (1991) (13)
- International Psychopharmacology Algorithm Project Report. (1995) (13)
- Are monoamine metabolites in cerebrospinal fluid worth measuring? (1993) (13)
- Clinical investigation of monoamine neurotransmitter interactions (2005) (13)
- Mechanisms of action of antipanic drugs (1990) (13)
- Public–private partnerships to revitalize psychiatric drug discovery (2014) (13)
- G-Protein Level Quantification in Platelets and Leukocytes from Patients with Panic Disorder (1996) (13)
- A survey of psychotropic medications not available in the United States. (1991) (13)
- Effect of IL-1α on the release of norepinephrine in rat hypothalamus (1998) (13)
- Effects of chronic lithium treatment on platelet PKC isozymes in Alzheimer's and elderly control subjects (1993) (13)
- Combined Lithium and Electroconvulsive Therapy: Pharmacokinetic and Pharmacodynamic Interactions. (1987) (12)
- Pharmacologic profile of natural products used to treat psychotic illnesses. (1995) (12)
- ECT alters human monoamines in a different manner from that of antidepressant drugs. (1988) (12)
- Redirecting the revolution: new developments in drug development for psychiatry (2019) (12)
- Nortriptyline formation after single oral and intramuscular doses of amitriptyline (1982) (12)
- Guanine nucleotide binding proteins in opioid-dependent patients (1997) (12)
- Platelet α2-adrenoreceptors in depression: a critical examination (1993) (12)
- A pharmacodynamic study of the α2‐adrenergic receptor antagonist ethoxyidazoxan in healthy volunteers (1994) (12)
- Temporal association between depression-dependent dyskinesias and high urinary phenylethylamine output. (1983) (12)
- Lymphocyte β-Adrenergic Receptor Modification in Bulimia (1988) (12)
- Diurnal variation in the concentrations of catecholamines and indoleamines in the median eminence and in the intermediate and posterior lobes of the pituitary gland of the male rat (1989) (12)
- Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. (1997) (11)
- CSF, plasma, and urine: what do concomitant measurements of norepinephrine and its metabolites mean? (1985) (11)
- Optimizing early Go/No Go decisions in CNS drug development (2015) (11)
- Clinical response to clozapine in patients with schizophrenia. (1994) (11)
- Chronic exposure of C6 glioma cells to desipramine desensitizes beta-adrenoceptors, but increases KL/KH ratio. (1991) (11)
- Bupropion, ECT, and dopaminergic overdrive. (1991) (11)
- Effects of chronic desipramine on plasma norepinephrine concentrations and cardiovascular parameters in elderly depressed women: a preliminary report. (1984) (11)
- Regional brain glucose metabolism after acute α2‐blockade by idazoxan (1995) (10)
- In Vivo Evidence that Nonneuronal β‐Adrenoceptors as Well as Dopamine Receptors Contribute to Cyclic AMP Efflux in Rat Striatum (1994) (10)
- Quantitative autoradiography of beta-adrenoceptors in the cardiac vagus ganglia of the rat. (1988) (10)
- Psychotropic medications and work performance. (1990) (10)
- The Relationship between Brain Receptor Occupancy and Alerting Effects in Humans Support MK-0249 and MK-3134 As Inverse Agonists at the Histamine Subtype-3 Pre-synaptic Receptor (2009) (10)
- Benefits Exceed Risks of Newer Antidepressant Medications in Youth—Maybe Not (2009) (9)
- Dose-dependent effects of intravenous alprazolam on neuroendocrine, biochemical, cardiovascular, and behavioral parameters in humans (2005) (9)
- Noradrenergic Function in Affective Illness (1979) (9)
- Disparate serum thioridazine concentrations: liquid chromatography versus radioreceptor assay. (2009) (9)
- Binding of imipramine to plasma protein and to brain tissue: Relationship to CSF tricyclic levels in man (1979) (9)
- Interethnic dissociation between debrisoquine and desipramine hydroxylation. (1985) (9)
- Methodological considerations for the development of new treatments for bipolar disorder. (1999) (9)
- Pharmacological issues in the treatment of bipolar disorder: focus on mood-stabilizing compounds. (1993) (9)
- Ten day administration of desipramine produces an increase in KL/KH for beta-receptors in rat hippocampus. (1989) (9)
- Biochemical classifications of diagnostic subgroups and D-type scores. (1989) (9)
- Biomarkers in psychotropic drug development. (2002) (9)
- Tissue localization of 7- and 8-hydroxychlorpromazines. (1974) (8)
- Zimelidine and norzimelidine protein binding measured by equilibrium dialysis and cerebrospinal fluid (1982) (8)
- Active metabolites of tricyclic antidepressants (1981) (8)
- Comparative pharmacokinetics of zimelidine and desipramine in man following acute and chronic administration (1979) (8)
- Disparate Biochemical Actions of Electroconvulsive Therapy and Antidepressant Drugs. (1988) (8)
- Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology (2014) (8)
- The NIMH ‘Fast-Fail Trials’ (FAST) Initiative: Rationale, Promise, and Progress (2020) (8)
- New Era for Novel CNS Drug Development (2012) (8)
- Crossover study of zimelidine and desipramine in depression: evidence for amine specificity [proceedings]. (1981) (8)
- Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study. (1994) (8)
- Accidental antidepressants: search for specific action. (1987) (7)
- BIOMARKERS AND NEUROBEHAVIORAL DIAGNOSIS. (2021) (7)
- Characterization of beta 1- and beta 2-adrenoceptor subtypes in the rat sinoatrial node and stellate ganglia by quantitative autoradiography. (1989) (7)
- Chronic alpha-2 antagonism increases norepinephrine, blocks GH release, and is antidepressant (1989) (7)
- Effects of chronic exposure to ethanol alone and in combination with desipramine on beta-adrenoceptors of rat brain. (1990) (7)
- Idazoxan down-regulates β-adrenoceptors on C6 glioma cells in vitro (1992) (6)
- MONOAMINERGIC ACTIONS OF ECT (1992) (6)
- Axonal transport of angiotensin-converting enzyme in the rat striatonigral pathway (1988) (6)
- Acute alpha 2 blockade by idazoxan increases insulin and lowers plasma glucose during positron emission tomography. (1997) (6)
- Effects of psychotropic drugs on neurotransmitters in man. (1987) (6)
- Norepinephrine in the Affective Disorders: Receptor Assessment Strategies (1985) (6)
- Amelioration of Psychosis with Carbidopa: A Case Report (1984) (6)
- Effect of IL-1alpha on the release of norepinephrine in rat hypothalamus. (1998) (6)
- Metabolism of tri cyclic anti depressants in human liver microsomes (1981) (6)
- Dosage regimen design for cyclic antidepressants: a review of pharmacokinetic methods. (1991) (5)
- Dopamine D1 receptor in rat brain: a quantitative autoradiographic study with 125I-SCH 23982. (1987) (5)
- Biological Theories of Depression and Implications for Current and New Treatments (2011) (5)
- Characterization of / 3 jand / 32-Adrenoceptor Subtypes in the Rat Atrioventricular Node by Quantitative Autoradiography (2005) (5)
- Dose ranging for trials through biomarkers of drug effects (2010) (5)
- Psychotherapeutic drugs and biogenic amines. Current concepts and therapeutic implications. (1984) (4)
- Responses to alpha 2-adrenoceptor blockade by idazoxan in healthy male and female volunteers. (1997) (4)
- Clinical Efficacy and Target Engagement of Glutamatergic Drugs: Placebo-Controlled RCTs of Pomaglumetad and TS-134 for Reversal of Ketamine-Induced Psychotic Symptoms and PharmacoBOLD in Healthy Volunteers (2020) (4)
- Biochemical effects of selective serotonin-reuptake inhibitors in man (1988) (4)
- Acute noradrenergic effects of desipramine in depression. (1991) (4)
- Regional brain glucose metabolism after acute alpha 2-blockade by idazoxan. (1995) (4)
- Pharmacokinetic and dynamic correlates of intravenous alprazolam challenge (1991) (4)
- Chronic Lithium Administration Enhances Noradrenergic Responses to Intravenous Administration of the α2 Antagonist Idazoxan in Healthy Volunteers (2004) (4)
- Cerebral glucose metabolic and plasma catecholamine responses to the α2 adrenoceptor antagonist ethoxyidazoxan given to healthy volunteers (1999) (4)
- Introduction: Norepinephrine as an ‘umbrella’ neuromodulators (1986) (4)
- Norepinephrine in the Affective Disorders: Classic Biochemical Approaches (1985) (4)
- Mining the secrets of the CSF: developing biomarkers of neurodegeneration. (2012) (4)
- ECT and delirium in Parkinson's disease. (1992) (4)
- Neurotransmitter interactions as a target of drug action. (1989) (3)
- Lymphocyte beta-adrenergic receptor modification in bulimia. (1988) (3)
- Treatment of major depression: selection of initial drug. (1997) (3)
- The effect of clorgyline on noradrenergic function (2004) (3)
- The study of possible influences of licit and illicit drugs on driver behavior (1971) (2)
- Hydroxy metabolite concentrations: role of renal clearance (1983) (2)
- Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium. (2015) (2)
- Current drug development for antidepressants and ideas addressing downstream glutamate: the ketamine example (2014) (2)
- Novel prodrug PRX-P4-003, selectively activated by gut enzymes, may reduce the risk of iatrogenic addiction and abuse. (2018) (2)
- Central Nervous System Trial Failures: Using the Fragile X Syndrome-mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human Trials. (2022) (2)
- Effects of chronic lithium treatment on signal transduction mechanisms in HL60 cells (1989) (2)
- ECT treatment does not enhance neuroendocrine responses to serotonergic challenge (1992) (2)
- The 5-HT1A Receptor: an unkept promise? (2000) (2)
- Combined fluoxetine and tricyclic antidepressants. (1989) (2)
- ECT methodologic issues. (1994) (2)
- Prediction of steady state plasma concentration of imipramine [proceedings]. (1978) (2)
- EFFECTS OF LITHIUM ON SIGNAL TRANSDUCTION IN HUMANS (1992) (2)
- A Reply to El-Mallakh. (1987) (2)
- Controlling the placebo response rates in depression (1998) (2)
- Alprazolam and aggression. (1989) (2)
- Comments on gender differences in pharmacokinetics and pharmacodynamics. (1993) (2)
- Promising medications not available in the United States (1994) (1)
- Dr. Golden and Associates Reply (2006) (1)
- Lithium and ECT Interaction. (1987) (1)
- Translating Glutamate : From Pathophysiology to Treatment Citation Javitt (2012) (1)
- Augmentation of neuroleptics with idazoxan: Focus on noradrenergic function in schizophrenia (1993) (1)
- S.08.01 The metabotropic glutamate receptor progress towards novel therapeutics (2003) (1)
- Carbamazepine increased pregnenolone synthesis blocked by peripheral type benzodiazepine receptor antagonist (1995) (1)
- Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology (2014) (1)
- Advances in Treatment and Perspectives for New Interventions in Mood and Anxiety Disorders (2003) (1)
- Key issues in the diagnosis and treatment of bipolar disorders. (1996) (1)
- Panic provocation studies with placebo (2000) (1)
- Valproate and mood disorders: perspectives. Introduction. (1992) (1)
- Psychotherapeutic Drugs and Biogenic Amines (1984) (1)
- S-25-5 Clinical onset of antidepressant action: Implications for new drug development (1996) (1)
- Duloxetine: Pharmacodynamic evidence of dual reuptake inhibition in healthy subjects (2002) (0)
- BUPROPION, ECT, AND DOPAMINERGIC OVERDRIVE. REPLY (1991) (0)
- Effects of desmethylimipramine on plasma norepinephrine pulse and blood pressure (1983) (0)
- Plasma antidepressant level changes: kinetics versus methods. (1986) (0)
- A Reply to Pearlman. (1988) (0)
- Effects of chronic lithium administration on the beta-adrenoceptors in rat frontal cortex and striatum (1989) (0)
- Side Effect Profile and Safety of Antidepressants in Light of New Therapeutic Indications (1997) (0)
- E.05.02 Making better early go/no-go decisions in drug development progress in the NIMH FAST-FAIL programme (2014) (0)
- Effects of antidepressant treatments on ‘whole body’ norepinephrine turnover (1983) (0)
- The Paired FDG Pet Scan Method: Validation Using Placebo Infusions (1994) (0)
- Clinical "Response" to "Convulsive" Therapy. (1985) (0)
- COMBINED MEASURES OF NORADRENERGIC OUTPUT AND RECEPTOR RESPONSIVITY IN DEPRESSION (1992) (0)
- 28-3 Future antidepressants: What is possible? (1997) (0)
- Reply to Comments by Dr. Balon (2007) (0)
- Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS) (2021) (0)
- Effects of drug washout on CSF monoamine and psychoendocrine variables. (1986) (0)
- Phenylethylamine and tyramine outputs in patients with affective disorders: behavioral and biochemical correlates. (1984) (0)
- NORADRENERGIC AND CARDIOVASCULAR EFFECTS OF CHRONIC S-ADENYOSYL-METHIONINE IN HEALTHY VOLUNTEERS (1986) (0)
- Norepinephrine as an 'umbrella' neuromodulator. (1986) (0)
- STEADY‐STATE PREDICTIONS BASED ON FIRST DOSE DATA (1992) (0)
- 324. Implications of a significant treatment by country interaction (1998) (0)
- 82-3 Hormones and antidepressants: implications for new drug development (1997) (0)
- A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia (2020) (0)
- Augmentation of Response to Typical Neuroleptic Treatment Using Idazoxan, an Alpha-2 Antagonist, in Patients with Schizophrenia (1994) (0)
- Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers (2023) (0)
- 119. Translating Neuroscience Into Drug Development: Evolving NIMH Strategy (2019) (0)
- Effects of typical and atypical neuroleptics on plasma and urinary monoamine metabolites (1989) (0)
- Methods to facilitate early exploratory testing of novel psychopharmacologic agents in humans. (1993) (0)
- Clinical Pharmacokinetics of Antidepressants (1984) (0)
- New Clinical Drug Evaluation Unit (NCDEU) annual meeting: a great opportunity for early career psychiatrists. (2012) (0)
- S-3-4 Depression and somatization: A neurochemical link? (1996) (0)
- Commentary on the management of treatment-resistant affective disorder: clinical perspectives (1992) (0)
- Major depression: The validity of a diagnosis (1993) (0)
- Better Approaches to Derisking Psychiatric Drug Development are Needed, Not New Funding Mechanisms (2022) (0)
- 274. Early clinical development of psychoactive drugs: Pro's and con's of academic collaborations (1998) (0)
- CSF 5-HIAA, personality, aggression, and social competence in childhood and adolescence (1989) (0)
- Two novel tools for evaluating GlyT1, a potential target for the treatment of shizophrenia (2008) (0)
- Advances in psychopharmacology: Predicting and improving treatment response CRC Press, Boca Raton, Florida (1984). 327 pp. $90. (U.S.A.); $103 (Foreign) Edited by Mark S. Gold, R. Bruce Lydiard, and John S. Carman (1985) (0)
- Introduction (1992) (0)
- Pharmacogenetics of Psychotropic Drugs: Pharmacogenetics in psychotropic drug discovery and development (2002) (0)
- HYDROXYLATED METABOLITES OF TRICYCLIC ANTIDEPRESSANTS: INHIBITION OF AMINE UPTAKE AND OTHER PRE-CLINICAL STUDIES (1979) (0)
- CSF homovanillic acid predicts behavioral response to stimulants in 47 ADHD boys (1995) (0)
- The Tricyclic Antidepressants (1986) (0)
- Different Doses of Neuroleptics for Genetically Different Groups (1984) (0)
- Idazoxan down-regulates beta-adrenoceptors on C6 glioma cells in vitro. (1992) (0)
- Psychotherapeutic Medications Development Program (PMDP). (1993) (0)
- In Memoriam Donald S. Robinson, MD (2022) (0)
- Discovering translational biomarkers in neurodevelopmental disorders (2018) (0)
- Evidence for rating distortion during study lead-in periods: Implications for study design and outcome (1998) (0)
- Proteomic Biomarkers for Brain Disorders: Technical Considerations and Challenges (2014) (0)
- P-18-16 Increased levels of Gαs in platelets of euthymic bipolar affective disorder patients (1996) (0)
- Drug Discovery and Development New Era for Novel CNS Drug Development (2012) (0)
- Refractory Depression: Is There a Next Step? (1994) (0)
- 116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients (2019) (0)
- Real changes can enhance information yield on novel psychopharmacologic agents (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With William Z. Potter?
William Z. Potter is affiliated with the following schools: